Compare Immunovant Inc. Common Stock (IMVT) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs New York Times Co — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while New York Times Co trades at $66.6 (market cap $10.47B). The key difference: New York Times Co is the larger of the two by market cap, and New York Times Co pays a 1.42% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and New York Times Co for 81 Days on average.
| IMVT | NYT | |
|---|---|---|
Market Cap | $6.62B | $10.47B |
Volume | 1,131,364 | 1,998,850 |
Sector | Health | Media |
52-Week High | $44.96 | $85.86 |
52-Week Low | $17.03 | $54.66 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $5.72B | $9.86B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
The New York Times Company (NYT) trades at $66.60, up 3.95% over the past 24 hours, with a bearish technical signal. Recent earnings have consistently beaten expectations, with Q1 and Q2 2026 EPS exceeding forecasts. Revenue and net income have shown steady growth from 2022 to 2025, with margins improving. The company declared a quarterly dividend of $0.23 per share, payable in October 2026. Analyst consensus is a 'Hold' with a price target of $84.00, suggesting potential upside from the current price.
Outlook remains mixed; strong fundamentals and earnings beats support growth, but a shareholder lawsuit and bearish technical indicators present near-term risks. The stock offers a dividend yield, and institutional interest is present, but investors should weigh legal uncertainties and market sentiment against solid financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
